{"id":"W4283326697","doi":"10.1097/01.hs9.0000843684.97625.7e","title":"S198: BET INHIBITOR PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS — JAK INHIBITOR-NAÏVE OR WITH SUBOPTIMAL RESPONSE TO RUXOLITINIB — PRELIMINARY DATA FROM THE MANIFEST STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Myeloproliferative neoplasm; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009799247,0.0006215119,0.001389343,0.0002605578,0.0002167649,0.000672474,0.0004160669,0.0006982547,0.005577995],"category_scores_gemma":[0.0008875871,0.0002122457,0.001379352,0.0003091416,0.0002317419,0.0005605707,0.0002401654,0.001533184,0.000903183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005794866,"about_ca_system_score_gemma":0.0006668869,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005901167,"about_ca_topic_score_gemma":0.002548539,"domain_scores_codex":[0.9997305,0.0001413892,0.00003003304,0.00003020388,0.00002821034,0.00003956064],"domain_scores_gemma":[0.999431,0.0001544209,0.0001332444,0.00003301039,0.00004421712,0.0002041621],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6737611,0.01532267,0.01877739,0.001994815,0.003330992,0.0006330428,0.0001943826,0.001984168,0.03742528,0.0003048772,0.01139728,0.2348741],"study_design_scores_gemma":[0.4599499,0.418009,0.09069175,0.0004056327,0.003302097,0.001279246,0.0001428501,0.002204127,0.00564222,0.0004024919,0.01790351,0.00006722102],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9752339,0.01253038,0.0005716365,0.001821112,0.0002264925,0.0009147396,0.003215618,0.0001318098,0.005354277],"genre_scores_gemma":[0.9850642,0.004194775,0.0009688857,0.00163869,0.0002815026,0.0005426808,0.005129036,0.00002102742,0.002159161],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005577995,"threshold_uncertainty_score":0.01866019,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02699854354408923,"score_gpt":0.266576492253164,"score_spread":0.2395779487090748,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}